A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from ...
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...
A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with ...
HighlightsMaiden resource estimate prepared in accordance with NI 43-101 standards of 5.32 million pounds Indicated and 1.04 million pounds Inferred - delivered just eight months after closing the ...
Ramp Metals Inc. (TSXV: RAMP) ("Ramp Metals" or the "Company") is pleased to report a 21m intercept grading 0.80% Cu, 17.01 g ...
Shares of Deutz AG, the Cologne-based engine manufacturer, experienced a pullback on Monday, shedding 2.54 percent to close at €10.37. This daily dip, however, stands in stark contrast to the equity's ...
Investors in Deutz AG are bracing for a pivotal week in May, as the German engine manufacturer's ambitious strategic pivot faces its first major financial examination. The company will release its ...
U.S. fighter jets scrambled to intercept Russian warplanes off the coast of Alaska. The Russian jets never entered U.S. airspace. NBC News’ Keir Simmons reports ...
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results